J. Lipid Res. Acyl Labeled PIP's available August 1, 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scoppola, A.
Right arrow Articles by Taylor, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scoppola, A.
Right arrow Articles by Taylor, G. W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol 32, 1057-1060, Copyright © 1991 by Lipid Research, Inc.

ARTICLES

Quantitation of plasma mevalonic acid using gas chromatography-electron capture mass spectrometry

A Scoppola, VM Maher, GR Thompson, NB Rendell and GW Taylor
Medical Research Council Lipoprotein Team, Hammersmith Hospital, London, U.K.

Circulating concentrations of mevalonic acid (MVA) change in parallel with, and may be used as a marker of cholesterol biosynthesis. Plasma MVA levels have been quantified using a sensitive and specific capillary gas chromatography-electron capture mass spectrometric assay. The detection limit for MVA in plasma is 100 pg/ml; the intra-assay variation is 5.11%; the inter-assay variation is 7.7%. Using this assay, the mean plasma MVA in 15 normolipidemic subjects was 2.37 +/- 1.2 ng/ml (range 0.41-5.31 ng/ml). Administration of 40 mg of simvastatin (an HMG-CoA reductase inhibitor) significantly accenutated the diurnal decrease in plasma MVA levels. This assay may be useful in investigating cholesterol synthesis rates in different dyslipidemias and individual responses of HMG-CoA reductase-inhibiting drugs.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Lipid Res.Home page
G. S. Saini, T. A. Wani, A. Gautam, B. Varshney, T. Ahmed, K. S. Rajan, K. K. Pillai, and J. K. Paliwal
Validation of the LC-MS/MS method for the quantification of mevalonic acid in human plasma and determination of the matrix effect
J. Lipid Res., October 1, 2006; 47(10): 2340 - 2345.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
P.O Bonetti, L.O Lerman, C Napoli, and A Lerman
Statin effects beyond lipid lowering--are they clinically relevant?
Eur. Heart J., February 1, 2003; 24(3): 225 - 248.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
E. R. Christ, M. H. Cummings, E. Albany, A. M. Umpleby, P. J. Lumb, A. S. Wierzbicki, R. P. Naoumova, M. A. Boroujerdi, P. H. Sönksen, and D. L. Russell-Jones
Effects of Growth Hormone (GH) Replacement Therapy on Very Low Density Lipoprotein Apolipoprotein B100 Kinetics in Patients with Adult GH Deficiency: A Stable Isotope Study
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 307 - 316.
[Abstract] [Full Text]

Home page
 J. Lipid Res.Home page
G. M. B. Berger, R. J. Pegoraro, S. B. Patel, P. Naidu, L. Rom, H. Hidaka, A. D. Marais, A. Jadhav, R. P. Naoumova, and G. R. Thompson
HMG-CoA reductase is not the site of the primary defect in phytosterolemia
J. Lipid Res., May 1, 1998; 39(5): 1046 - 1054.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 1991 by the American Society for Biochemistry and Molecular Biology.